<DOC> 
<DOCNO>1080521_business_story_9297836.utf8</DOCNO> 
<TEXT> 
         
The Telegraph - Calcutta (Kolkata) | Business | Dr Reddys net drops 40%
                                                                                                                                                                                                                                                                                                                                                                       Dr Reddys net drops 40%
          OUR SPECIAL CORRESPONDENT                          Bitter pill                                  
	Mumbai, May 20: Dr Reddys Laboratories Ltd (DRL), the Hyderabad-based pharmaceutical company, today reported a 40 per cent drop in net profit in the fourth quarter as pricing pressures continued. Net profit came down to Rs 162.26 crore from Rs 268.9 crore in the same period last year.        
	During the fourth quarter of 2006-07, DRL got a 180-day exclusivity to sell the generic version of GlaxoSmithKlines Zofran, which boosted its bottomline.        
	The companys topline also felt the heat and came down to Rs 1,038.47 crore in the fourth quarter from Rs 1,151.06 crore in the same period last year.        
	For the year as a whole, Dr Reddys posted a lower net profit of Rs 475.22 crore compared with Rs 1,176.86 crore for the year ended March 31, 2007.         
	Total income dropped from Rs 4,084.31 crore to Rs 3,585.01 crore.        
	According to DRL, key brands and new products positively impacted revenues, with Reditux, which was launched in April 2007, contributing Rs 15 crore to the topline.        
	In North America, revenues were lower at Rs 800 crore in 2007-08 against Rs 2,360 crore in the previous year.        
	On the other hand, revenues from Germany (Betapharm) stood at Rs 820 crore even with year-on-year sales volume growth at 26 per cent.        
	Pointing out that the years revenues reflected the impact of pricing pressure and supply constraints, DRL said revenues from custom pharmaceutical services business increased 53 per cent to Rs 190 crore from Rs 120 crore in the previous year.        
	Revenues from active pharmaceutical ingredients (API) were placed at Rs 1,200 crore in the year.        
	During the year, the company launched 89 generic products and made 397 filings across all markets.        
	Disappointment over the quarterly results led to the DRL share ending lower by 1.8 per cent at Rs 638.85 on the Bombay Stock Exchange today.                                                                                                                                     
</TEXT> 
</DOC>